May 10, 2024 | Featured, Maryland, News, Science
Bookmark (0) Please login to bookmarkClose Username or Email Address Password Remember Me EyeDNA Therapeutics, a subsidiary of Paris-based Coave Therapeutics, reported encouraging 24-month results for 17 adult patients in its Phase ½ PDE6B gene therapy clinical trial...
May 2, 2024 | Featured, Maryland, News, Science
Bookmark (0) Please login to bookmarkClose Username or Email Address Password Remember Me Atsena Therapeutics, a company developing innovative gene therapies for inherited retinal diseases, has reported both structural and functional vision improvements for patients...
Apr 19, 2024 | Featured, Maryland, News, Science
Bookmark (0) Please login to bookmarkClose Username or Email Address Password Remember Me SalioGen Therapeutics, a biotechnology company developing therapies for a broad range of conditions, including inherited retinal diseases, has announced development of SGT-1001,...
Apr 12, 2024 | Featured, Maryland, News, Science
Bookmark (0) Please login to bookmarkClose Username or Email Address Password Remember Me Johns Hopkins University (JHU) has launched a Phase 3 clinical trial of N-acetylcysteine (NAC) for the treatment of retinitis pigmentosa (RP). Known as NAC Attack, the 45-month...
Apr 11, 2024 | Featured, Maryland, News, Science
Bookmark (0) Please login to bookmarkClose Username or Email Address Password Remember Me ViGeneron GmbH, a gene therapy development company in Munich, Germany, has dosed the first patient in a Phase 1b clinical trial for its gene therapy for people with retinitis...
Apr 8, 2024 | Featured, Maryland, News, Science
Bookmark (0) Please login to bookmarkClose Username or Email Address Password Remember Me The biotech company Ocugen has announced that the US Food & Drug Administration has provided clearance for launch of its Phase 3 liMeliGhT clinical trial for OCU400, the...
